This Article Full Text Full Text (PDF) All Versions of this Article: 41/3/553    most recent 01.HYP.0000055779.93635.A2v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aggarwal, A. Articles by Kaye, D. M. Search for Related Content PubMed PubMed Citation Articles by Aggarwal, A. Articles by Kaye, D. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CLONIDINE Medline Plus Health Information Heart Failure Related Collections Cardio-renal physiology/pathophysiology Cardiovascular Pharmacology

(Hypertension. 2003;41:553.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Regional Sympathetic Effects of Low-Dose Clonidine in Heart Failure

From the Baker Medical Research Institute (A.A., M.D.E., G.L., D.M.K.) and the Department of Pharmacology (M.J.M.), University of Melbourne, Melbourne, Victoria, Australia.

Correspondence to Dr David M Kaye, Baker Medical Research Institute, PO Box 6492 St Kilda Rd Central, Melbourne, Victoria 8008, Australia. E-mail d.kaye{at}alfred.org.au

This study examined the effects of low doses of intravenous clonidine on regional and global sympathetic nervous system activity in heart failure. In heart failure, adrenoceptor-blocking treatments have a limited sphere of activity. Centrally acting sympatholytic therapies should be further investigated, with a specific emphasis on targeting cardiac and renal sympathetic overactivity. In 10 patients with moderate-severe congestive heart failure, we examined the effect of intravenous clonidine on systemic, cardiac, and renal sympathetic activity and on brain monoamine turnover using the norepinephrine spillover method. In addition, we assessed the effect of clonidine on cardiac release of the sympathetic cotransmitter neuropeptide Y. A dose of 1 µg/kg of clonidine resulted in a fall in cardiac (326±73 to 160±40 pmol/min, P<0.001), renal (2.5±0.6 to 1.5±0.3 nmol/min, P=0.01), and global norepinephrine spillover (4.0±0.6 to 3.1±0.5 nmol/min, P<0.01), with a significantly disproportionate reduction in cardiac versus total-body sympathetic activity (P<0.05). No significant changes in cardiac neuropeptide Y release or in central monoamine turnover were demonstrated. Clonidine, at modest doses, significantly attenuates cardiac and renal sympathetic tone in heart failure. In addition to the beneficial effects of antiadrenergic therapy in the heart, the renal sympatholytic effect may counter the salt and water retention that is a hallmark of the condition.

Key Words: heart failure • clonidine • renal • norepinephrine

This article has been cited by other articles:

				A. J. King, J. W. Osborn, and G. D. Fink Splanchnic Circulation Is a Critical Neural Target in Angiotensin II Salt Hypertension in Rats Hypertension, September 1, 2007; 50(3): 547 - 556. [Abstract] [Full Text] [PDF]

				A. J. King, N. Bari Olivier, P. S. Mohankumar, J. S. Lee, V. Padmanabhan, and G. D. Fink Hypertension caused by prenatal testosterone excess in female sheep Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1837 - E1841. [Abstract] [Full Text] [PDF]

				A. J. King and G. D. Fink Chronic Low-Dose Angiotensin II Infusion Increases Venomotor Tone by Neurogenic Mechanisms Hypertension, November 1, 2006; 48(5): 927 - 933. [Abstract] [Full Text] [PDF]

				W. S. Akers and L. A. Cassis Presynaptic modulation of evoked NE release contributes to sympathetic activation after pressure overload Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2151 - H2158. [Abstract] [Full Text] [PDF]